Abstract
Cancer is a complex group of diseases initiated by abnormal cell division with the potential of spreading to other parts of the body. The advancement in the discoveries of omics and bio- and cheminformatics has led to the identification of drugs inhibiting putative targets including vascular endothelial growth factor (VEGF) family receptors, fibroblast growth factors (FGF), platelet derived growth factors (PDGF), epidermal growth factor (EGF), thymidine phosphorylase (TP), and neuropeptide Y4 (NY4), amongst others. Drug resistance, systemic toxicity, and drug ineffectiveness for various cancer chemo-treatments are widespread. Due to this, efficient therapeutic agents targeting two or more of the putative targets in different cancer cells are proposed as cutting edge treatments. Heterocyclic compounds, both synthetic and natural products, have, however, contributed immensely to chemotherapeutics for treatments of various diseases, but little is known about such compounds and their multimodal anticancer properties. A compendium of heterocyclic synthetic and natural product multitarget anticancer compounds, their IC50, and biological targets of inhibition are therefore presented in this review.
Highlights
Cancer is a complex group of diseases the onset of which is characterized by abnormal cell division with the potential of spreading to other parts of the body over time [1,2]
Robles andclavatum co-workers identified possessing multitarget anticancer properties. They investigated its activity against have anticancer effect on HeLa cells through DNA damage, 5-LOX inhibition, G0/G1 cell cancer cell lines in vitro and in a xenograft mouse model of melanoma and found that 70 cycle arrest, deactivation of oxidation resistance (OXR) receptor and mitochondrion meminhibited proliferation of all of the following five triple-negative breast cancer cell lines brane depolarization
Anti-proliferative and cancer preventing properties of compound and its derivative fucoxanthinol, are mediated through different signaling pathways, including the caspases, B-cell lymphoma 2 (Bcl-2) proteins, mitogen-activated protein kinase (MAPK), PI3K/Akt, JAK/STAT, AP-1, GADD45, and 29 of several other molecules that are involved in cell cycle arrest, apoptosis, anti-angiogenesis, or inhibition of metastasis (Figure 32) [214]
Summary
Cancer is a complex group of diseases the onset of which is characterized by abnormal cell division with the potential of spreading to other parts of the body over time [1,2]. Challenges associated with cancer treatments such as drug resistance, systemic toxicity of administered drugs, and drug ineffectiveness are widespread [32,33] Confounding factors such as the multiple signaling nature of pathways and the propensity of most cancer cells to mutate have hindered the search for an effective therapeutic agent for combating cancers, calling for urgent search to identify new anticancer agents as drug leads [19,34]. To overcome these challenges, multi-target heterocyclic inhibitors are proposed as an option in achieving success in the fight against various forms of cancers. Original hard copy offprints of published papers in our various personal archives were consulted for relevant information [38,39]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
